Replies to post #177921 on Biotech Values

[DewDiligence]

BMY, INCY ink clinical collaboration to test BMY’s nivolumab and INCY’s INCB24360 in phase-1/2 trial:

http://www.fiercebiotech.com/press-releases/bristol-myers-squibb-and-incyte-enter-clinical-collaboration-agreement-eval-0

The study, which is expected to begin in the fourth quarter of 2014, will be co-funded by the companies and conducted by Incyte. Additional details of the collaboration were not disclosed.

When it comes to phase-2 clinical collaborations, immuno-oncology is the “new HCV.”

[DewDiligence]

AZN/JNJ/PCYC ink clinical collaboration for MEDI4736 + Imbruvica phase-2 trial:

http://finance.yahoo.com/news/astrazeneca-pharmacyclics-janssen-partner-immuno-130000558.html